Oncology Industry Analysis
Learn more about Oncology in the Pharma & Healthcare industry. Reports provide information on Current & Future Therapies for Cancer and Forecasting.
previous
| Analytical Tool - Protein Kinase Inhibitors in Oncology (BSK00044) "Analytical Tool - Protein Kinase Inhibitors in Oncology" offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in the drug development of protein kinase... | May 2012 | £3,670 |
| Competitive Insights to Protein Kinase Therapeutics in Oncology (BSK00564) The Faster Route to Consider Your Options and Position of OthersThis report represents a new and unique way of stratifying and analyzing the global protein kinase drug pipeline in oncology towards personalized medicine. It will excel your competitive awareness and... | May 2012 | £2,435 |
| Orphan Diseases Therapeutics in Oncology to 2018 (GBI00390) Strongly Diversified Developmental Pipelines Indicate Long-Term Growth Potential despite Moderate Scope of Current Late Stage MoleculesOrphan Diseases Therapeutics in Oncology to 2018 - Strongly Diversified Developmental Pipelines Indicate Long-Term Growth Potential despite Moderate Scope of Current Late Stage Molecules Summary GBI Research, the leading business intelligence provider,... | Apr 2012 | £2,210 |
| Colorectal Cancer Drug Futures (ESP00727) Early-Stage Colorectal Cancer (Crc) Is Generally Treated with Surgery and Radiation.... ....with a high percentage of patients going on to survive disease free. Unfortunately, only around 40% of CRCs are found... | Apr 2012 | £1,495 |
| Breast Cancer Drug Futures (ESP00731) Globally, Breast Cancer Is The Second Most Common Cancer after Lung Cancer.... ....and the most common cancer for women. IT is the second most common cause of death from cancer... | Apr 2012 | £1,495 |
| Retinoblastoma – Pipeline Review (GMD16721) H1 2012Retinoblastoma - Pipeline Review, H1 2012 Summary Global Markets Direct's, 'Retinoblastoma - Pipeline Review, H1 2012', provides an overview of the Retinoblastoma therapeutic pipeline. This report provides information on the therapeutic development... | Mar 2012 | £315 |
| Chronic Lymphocytic Leukemia (CLL) – Pipeline Review (GMD17398) H1 2012Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2012 Summary Global Markets Direct's, 'Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2012', provides an overview of the Chronic Lymphocytic Leukemia (CLL) therapeutic... | Mar 2012 | £315 |
| Xgeva's Safety and Efficacy Failings Put Future of Amgen Drug in Question (GDA28883) Xgeva's Safety and Efficacy Failings Put Future of Amgen Drug in Question Summary GlobalData, the industry analysis specialist, has released its new report, "Xgeva's Safety and Efficacy Failings Put Future of Amgen... | Feb 2012 | £315 |
| Liposarcoma Therapeutics (GDA28294) Pipeline Assessment and Market Forecasts to 2019Liposarcoma Therapeutics - Pipeline Assessment and Market Forecasts to 2019 Summary GlobalData, the industry analysis specialist, has released its new report, "Liposarcoma Therapeutics - Pipeline Assessment and Market Forecasts to 2019". The... | Feb 2012 | £2,520 |
| Nasopharyngeal Cancer Therapeutics (GDA28302) Pipeline Assessment and Market Forecasts to 2019Nasopharyngeal Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2019 Summary GlobalData, the industry analysis specialist, has released its new report, "Nasopharyngeal Cancer Therapeutics - Pipeline Assessment and Market Forecasts to... | Feb 2012 | £2,520 |
| Rhabdomyosarcoma Therapeutics (GDA26398) Pipeline Assessment and Market Forecasts to 2019Rhabdomyosarcoma Therapeutics - Pipeline Assessment and Market Forecasts to 2019 Summary GlobalData, the industry analysis specialist, has released its new report, "Rhabdomyosarcoma Therapeutics - Pipeline Assessment and Market Forecasts to 2019". The... | Feb 2012 | £2,520 |
| Laryngeal Cancer Therapeutics (GDA26424) Pipeline Assessment and Market Forecasts to 2019Laryngeal Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2019 Summary GlobalData, the industry analysis specialist, has released its new report, "Laryngeal Cancer Therapeutics - Pipeline Assessment and Market Forecasts to... | Feb 2012 | £2,520 |
| Melanoma Therapeutics (GDA07286) Pipeline Assessment and Market Forecasts to 2019Melanoma Therapeutics - Pipeline Assessment and Market Forecasts to 2019 Summary GlobalData, the industry analysis specialist, has released its new report, "Melanoma Therapeutics - Pipeline Assessment and Market Forecasts to 2019". The... | Feb 2012 | £2,520 |
| Chemotherapy-Induced Nausea and Vomiting (CINV) Therapeutics (GDA26421) Pipeline Assessment and Market Forecasts to 2019Chemotherapy-Induced Nausea and Vomiting (CINV) Therapeutics - Pipeline Assessment and Market Forecasts to 2019 Summary GlobalData, the industry analysis specialist, has released its new report, "Chemotherapy-Induced Nausea and Vomiting (CINV) Therapeutics -... | Feb 2012 | £2,520 |
| Analytical Tool - Apoptosis in Oncology (BSK00093) 'Analytical Tool - Apoptosis in Oncology' offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in apoptotic drug development for the treatment of cancer.... | Feb 2012 | £2,560 |
| Analytical Tool - Peptides in Oncology (BSK00089) 'Analytical Tool- Peptides in Oncology' offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in peptide drug development for the treatment of cancer. It... | Feb 2012 | £2,560 |
| Analytical Tool - Antibodies and Peptides in Oncology (BSK00533) 'Analytical Tool - Antibodies and Peptides in Oncology' offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in R&D and business development in the... | Feb 2012 | £4,910 |
| Cytokine Therapy in Oncology Drug Pipeline Update 2012 (BSK00082) There are today 82 companies plus partners developing 104 cytokine drugs in 204 developmental projects in cancer. In addition, there are 2 suspended drugs and the accumulated number of ceased... | Feb 2012 | £825 |
| Cellular Therapy in Oncology Drug Pipeline Update 2012 (BSK00084) There are today 67 companies plus partners developing 51 cellular therapy drugs in 100 developmental projects in cancer. In addition, there are 3 suspended drugs and the accumulated number of... | Feb 2012 | £825 |
| Peptides in Oncology Drug Pipeline Update 2012 (BSK00079) There are today 214 companies plus partners developing 196 peptide drugs in 427 developmental projects in cancer. In addition, there are 5 suspended drugs and the accumulated number of ceased... | Feb 2012 | £1,235 |
| Proteins in Oncology Drug Pipeline Update 2012 (BSK00524) This drug pipeline update covers proteins, excluding antibodies, as drugs for the treatment of cancer. There are today 306 companies plus partners developing 332 protein drugs in 570 developmental projects in... | Feb 2012 | £1,235 |
| Angiogenesis in Oncology Drug Pipeline Update 2012 (BSK00036) There are today 231 companies plus partners developing 224 angiogenesis drugs in 965 developmental projects in cancer. In addition, there are 5 suspended drugs and the accumulated number of ceased... | Feb 2012 | £1,235 |
| Antibodies in Oncology Drug Pipeline Update 2012 (BSK00013) The commercial and therapeutic success of antibodies like Rituxan, Avastin, and Erbitux will force the industry to look into the next generation of therapeutic antibodies, preparing themselves for the second... | Feb 2012 | £1,235 |
| Apoptosis in Oncology Drug Pipeline Update 2012 (BSK00052) Cancer cells frequently and possibly invariably possess apoptotic defects. In this context, apoptotic pathways provide exciting molecular targets for new therapeutic agents to specifically promote apoptosis of cancer cells. There are... | Feb 2012 | £1,235 |
| Gene Therapy in Oncology Drug Pipeline Update 2012 (BSK00083) There are today 116 companies plus partners developing 104 gene therapy drugs in 246 developmental projects in cancer. In addition, there are 4 suspended drugs and the accumulated number of... | Feb 2012 | £1,235 |
